Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease

Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.

Recent articles in left column more or less in alphabetical order classified

Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

If you want to support us you can do so through a donation: See registration OPS

Overall: chance of getting half and / or other form of cancer after successful treatment and survival of non-Hodgkin was significantly higher compared to people who never had cancer.

May 23, 2006: Source: Cancer. 2006 May 17;

A large study on 30 years follow-up shows that half of getting another cancer for non-Hodgkin's Patients previously treated for their success is significantly greater than for people who have never had non-Hodgkin's. What the reason is not listed because there is no overall difference was between whether or not to have had radiation. But again for people under 25 years at time of first treatment. Oi like the chemo and radiation which are often given in standard treatment of non-Hodgkin's not promote the risk of another cancer. But to be clear this is not a proven statement, but a thought of me personally.

RESULTS: There were 5638 patients who half developed cancer, which is significantly more than the number endemic. (O / E, 1.14, P <.001). Overall view: patients who had not been irradiated had as great a risk compared to patients who were irradiated. (Relative risk, 1.04, 95% confidence interval, 0.98-1.10, P = .21). Patients who were irradiated had a massively increased Concentrations of developing later Sarcomas, breast cancer, and mesothelioma compared to non-irradiated patients (P <.05). Patients aged younger than 25 years at the time of initial diagnosis had the highest relative risk increased. (No radiation: O / E, 2.1, P <.05, although radiation: O / E 4.51, P <.05). Overall, no statistical difference was seen between men and women. (O / E, 1.12 vs.. 1.15, respectively). Female survivors of non-Hodgkin seem less likely to develop breast cancer when compared with the general population (O / E, 0.85, P <.05), but women younger than 25 years at the time of first treatment to non Hodgkin-like just an increased risk of later developing breast cancer.

The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin's lymphoma.

Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK.
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah.

BACKGROUND: Survivors of non-Hodgkin lymphoma (NHL) are at Increased Risk for Developing secondary malignancies. For the current study, the authors quantitated this risk in a group of NHL survivors over 30 years of follow-up.

METHODS: Standardized incidence ratios (observed-to-expected [O / E] ratio) and absolute excess risk of secondary malignancies Were assessed in 77,876 Patients who Were diagnosed with NHL Between 1973 and 2001 from centers That participated in the National Cancer Institute's Surveillance, Epidemiology, and End Results Program.

RESULTS: There Were 5638 Patients who Developed secondary malignancies, significantly more Than the endemic rate (O / E, 1.14, P <.001). Overall, irradiated patient experienced a similar risk of secondary malignancies compared with unirradiated patiënten (relative risk, 1.04, 95% confidence interval, 0.98-1.10, P = .21). Irradiated Patients had an excess risk for Sarcomas, breast cancers, and mesothelioma compared with unirradiated survivors (P <.05). Patients age <25 years at the time of Their diagnosis was The Highest NHL Increased relative risk (no radiation: O / E, 2.1, P <.05; radiation: O / E 4.51, P <.05). Overall, no statistical difference was observed for secondary cancer incidence Between females and males (O / E, 1.12 vs.. 1.15, respectively). Female survivors of NHL Were Less Likely to Develop Breast Cancer Than the general population (O / E, 0.85, P <.05), but women age <25 years at the time of Their NHL diagnosis Were more Likely to Develop Breast Cancer (no radiation: O / E, 2.1, P <.05; radiation: O / E 4.51, P <.05).

CONCLUSIONS: The overall risk of secondary malignancies was Increased for NHL survivors and VARIED According To Age at NHL diagnosis, gender, and treatment. Cancer 2006. (C) 2006 American Cancer Society. PMID: 16708354 [PubMed - as supp song by publisher]